1006-P: Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital—The Cyber GEMS Randomized Controlled Trial Protocol

Introduction 58% reported an annual income 20, 000. Participants had an average maximum glucose of M: 315 ± 80. 6 mg/dL prior to enrollment, an T2D duration of M = 17. 3 ± 12. 1 years; 92% were CGM naive. Average duration in the study was 3. 7 days. Conclusion: The Cyber GEMS protocol is uniquely designed to evaluate the value and utility of real-time CGM for optimizing hospital glucose management in a high-risk, underserved T2D population. Lessons learned and implications for hospital based CGM use will be presented. Disclosure S. R. Spierling Bagsic: None. A. L. Fortmann: None. A. Bastian: None. R. Belasco: None. H. Sandoval: None. S. Lohnes: Consultant; Dexcom, Inc. L. Talavera: None. A. Philis-Tsimikas: Advisory Panel; Dexcom, Inc. , Lilly Diabetes, Novo Nordisk, Sanofi, Medtronic, Bayer Inc. Funding NIH NIDDK (1R01 DK124427-01A1)